SG11202010528XA - Combinations for treating cancer - Google Patents
Combinations for treating cancerInfo
- Publication number
- SG11202010528XA SG11202010528XA SG11202010528XA SG11202010528XA SG11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA SG 11202010528X A SG11202010528X A SG 11202010528XA
- Authority
- SG
- Singapore
- Prior art keywords
- combinations
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664356P | 2018-04-30 | 2018-04-30 | |
| PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010528XA true SG11202010528XA (en) | 2020-11-27 |
Family
ID=66794041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010528XA SG11202010528XA (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210030718A1 (https=) |
| EP (1) | EP3787620A1 (https=) |
| JP (1) | JP2021522246A (https=) |
| KR (1) | KR20210005182A (https=) |
| CN (1) | CN112040944A (https=) |
| AU (1) | AU2019263026B2 (https=) |
| BR (1) | BR112020022020A2 (https=) |
| CA (1) | CA3097486A1 (https=) |
| EA (1) | EA202092540A1 (https=) |
| MA (1) | MA52499A (https=) |
| MX (1) | MX2020011453A (https=) |
| SG (1) | SG11202010528XA (https=) |
| TW (1) | TW202014184A (https=) |
| WO (1) | WO2019211721A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158321A1 (en) * | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
| JP2023510135A (ja) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | 大環状化合物 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014001255B1 (pt) | 2011-07-19 | 2019-07-02 | Merck Sharp & Dohme B.V. | Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto |
| CA2956550A1 (en) * | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| PT3445767T (pt) * | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
| CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/zh unknown
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/es unknown
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 EA EA202092540A patent/EA202092540A1/ru unknown
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/ko not_active Ceased
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/ja not_active Withdrawn
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/pt not_active IP Right Cessation
- 2019-04-29 MA MA052499A patent/MA52499A/fr unknown
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/zh active Pending
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20210030718A1 (en) | 2021-02-04 |
| EP3787620A1 (en) | 2021-03-10 |
| CN112040944A (zh) | 2020-12-04 |
| CA3097486A1 (en) | 2019-11-07 |
| JP2021522246A (ja) | 2021-08-30 |
| AU2019263026B2 (en) | 2022-06-30 |
| EA202092540A1 (ru) | 2021-03-17 |
| WO2019211721A1 (en) | 2019-11-07 |
| MX2020011453A (es) | 2020-12-07 |
| BR112020022020A2 (pt) | 2021-02-02 |
| MA52499A (fr) | 2021-04-14 |
| KR20210005182A (ko) | 2021-01-13 |
| TW202014184A (zh) | 2020-04-16 |
| AU2019263026A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287907A (en) | Cancer treatment methods | |
| IL270720A (en) | Combination of treatments for cancer treatment | |
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| EP3641770A4 (en) | CANCER TREATMENT METHODS | |
| IL273395A (en) | Combined therapies for cancer treatment | |
| IL255060A0 (en) | Combined treatment for cancer | |
| EP3407978A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| IL277861A (en) | Antibodies specific to AXL for cancer treatment | |
| GB201903546D0 (en) | Cancer treatment | |
| EP3892282A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| PT3576740T (pt) | Tratamento de cancro | |
| IL268463A (en) | Cancer treatment | |
| GB201820660D0 (en) | Cancer treatments | |
| EP3706770A4 (en) | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER | |
| GB201706451D0 (en) | Cancer treatment | |
| IL282093A (en) | Combination therapy for cancer | |
| IL274626A (en) | Cancer treatment | |
| IL268416A (en) | Pharmaceutical combinations for cancer treatment | |
| IL287652A (en) | Cancer treatment | |
| SG11202010528XA (en) | Combinations for treating cancer | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| IL285466A (en) | Cancer treatment | |
| GB201814487D0 (en) | Cancer | |
| GB201800733D0 (en) | Cancer | |
| IL255016A0 (en) | Cancer treatment methods |